Australia markets closed

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.75+0.10 (+1.31%)
At close: 04:00PM EDT
7.90 +0.15 (+1.94%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 481.69M
Enterprise value 256.29M
Trailing P/E 315.25
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)169.39
Price/book (mrq)2.05
Enterprise value/revenue 91.37
Enterprise value/EBITDA -2.36

Trading information

Stock price history

Beta (5Y monthly) 2.28
52-week change 3148.38%
S&P500 52-week change 322.38%
52-week high 313.70
52-week low 32.65
50-day moving average 39.13
200-day moving average 36.23

Share statistics

Avg vol (3-month) 3629.1k
Avg vol (10-day) 3413.8k
Shares outstanding 562.15M
Implied shares outstanding 662.15M
Float 838.55M
% held by insiders 11.40%
% held by institutions 199.51%
Shares short (15 Apr 2024) 42.53M
Short ratio (15 Apr 2024) 44.35
Short % of float (15 Apr 2024) 45.08%
Short % of shares outstanding (15 Apr 2024) 44.08%
Shares short (prior month 15 Mar 2024) 42.39M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-3,213.78%

Management effectiveness

Return on assets (ttm)-28.56%
Return on equity (ttm)-44.84%

Income statement

Revenue (ttm)2.81M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)27.20%
Gross profit (ttm)N/A
EBITDA -108.49M
Net income avi to common (ttm)-97.33M
Diluted EPS (ttm)-1.59
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)236.22M
Total cash per share (mrq)3.81
Total debt (mrq)10.82M
Total debt/equity (mrq)4.60%
Current ratio (mrq)17.71
Book value per share (mrq)3.80

Cash flow statement

Operating cash flow (ttm)-90.97M
Levered free cash flow (ttm)-56.72M